BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 15571958)

  • 41. Detection of N-myc amplification by FISH in immature areas of fixed neuroblastomas: more efficient than Southern blot/PCR.
    Sartelet H; Grossi L; Pasquier D; Combaret V; Bouvier R; Ranchère D; Plantaz D; Munzer M; Philip T; Birembaut P; Zahm JM; Bergeron C; Gaillard D; Pasquier B
    J Pathol; 2002 Sep; 198(1):83-91. PubMed ID: 12210067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR.
    Anderson J; Gibson S; Williamson D; Rampling D; Austin C; Shipley J; Sebire N; Brock P
    Pediatr Blood Cancer; 2006 Jun; 46(7):820-4. PubMed ID: 16220551
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential polymerase chain reaction with serial dilutions for quantification of MYCN gene amplification in neuroblastoma.
    Gallego S; Reventos J; Sanchez de Toledo J; Munell F
    Anticancer Res; 1998; 18(2A):1211-5. PubMed ID: 9615790
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
    Bown N; Lastowska M; Cotterill S; O'Neill S; Ellershaw C; Roberts P; Lewis I; Pearson AD;
    Med Pediatr Oncol; 2001 Jan; 36(1):14-9. PubMed ID: 11464868
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detection of MYCN gene amplification and deletions of chromosome 1p in neuroblastoma by in situ hybridization using routine histologic sections.
    Leong PK; Thorner P; Yeger H; Ng K; Zhang Z; Squire J
    Lab Invest; 1993 Jul; 69(1):43-50. PubMed ID: 8331897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1.
    Hiyama E; Hiyama K; Ohtsu K; Yamaoka H; Fukuba I; Matsuura Y; Yokoyama T
    Med Pediatr Oncol; 2001 Jan; 36(1):67-74. PubMed ID: 11464909
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma.
    Kuroda T; Morikawa N; Matsuoka K; Fujino A; Honna T; Nakagawa A; Kumagai M; Masaki H; Saeki M
    J Pediatr Surg; 2008 Dec; 43(12):2182-5. PubMed ID: 19040931
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression.
    Mosse YP; Diskin SJ; Wasserman N; Rinaldi K; Attiyeh EF; Cole K; Jagannathan J; Bhambhani K; Winter C; Maris JM
    Genes Chromosomes Cancer; 2007 Oct; 46(10):936-49. PubMed ID: 17647283
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience.
    Canete A; Gerrard M; Rubie H; Castel V; Di Cataldo A; Munzer C; Ladenstein R; Brichard B; Bermúdez JD; Couturier J; de Bernardi B; Pearson AJ; Michon J
    J Clin Oncol; 2009 Mar; 27(7):1014-9. PubMed ID: 19171715
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
    Campbell K; Gastier-Foster JM; Mann M; Naranjo AH; Van Ryn C; Bagatell R; Matthay KK; London WB; Irwin MS; Shimada H; Granger MM; Hogarty MD; Park JR; DuBois SG
    Cancer; 2017 Nov; 123(21):4224-4235. PubMed ID: 28696504
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome.
    Fischer M; Oberthuer A; Brors B; Kahlert Y; Skowron M; Voth H; Warnat P; Ernestus K; Hero B; Berthold F
    Clin Cancer Res; 2006 Sep; 12(17):5118-28. PubMed ID: 16951229
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease.
    Mora J; Cheung NK; Chen L; Qin J; Gerald W
    Cancer; 2001 Jan; 91(2):435-42. PubMed ID: 11180092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Yeast artificial chromosome (YAC) vector cloning of the MYCN amplified domain in neuroblastomas.
    Schneider SS; Zehnbauer BA; Vogelstein B; Brodeur GM
    Prog Clin Biol Res; 1991; 366():71-6. PubMed ID: 2068181
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome.
    Spitz R; Oberthuer A; Zapatka M; Brors B; Hero B; Ernestus K; Oestreich J; Fischer M; Simon T; Berthold F
    Genes Chromosomes Cancer; 2006 Dec; 45(12):1130-42. PubMed ID: 16958102
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of MYCN Copy Number Heterogeneity by Direct FISH Analysis of Neuroblastoma Preparations.
    Squire JA; Thorner P; Marrano P; Parkinson D; Ng YK; Gerrie B; Chilton-Macneill S; Zielenska M
    Mol Diagn; 1996 Dec; 1(4):281-289. PubMed ID: 10462574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Two-dimensional DNA electrophoresis identifies novel CpG islands frequently coamplified with MYCN in neuroblastoma.
    Wimmer K; Zhu XX; Lamb BJ; Kuick R; Ambros P; Kovar H; Thoraval D; Elkahloun A; Meltzer P; Hanash SM
    Med Pediatr Oncol; 2001 Jan; 36(1):75-9. PubMed ID: 11464910
    [TBL] [Abstract][Full Text] [Related]  

  • 57. N-myc amplification and cell proliferation rate in human neuroblastoma.
    Pession A; Trerè D; Perri P; Rondelli R; Montanaro L; Mantovani W; Derenzini M; Paolucci G
    J Pathol; 1997 Nov; 183(3):339-44. PubMed ID: 9422991
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.
    Simon T; Spitz R; Faldum A; Hero B; Berthold F
    J Pediatr Hematol Oncol; 2004 Dec; 26(12):791-6. PubMed ID: 15591897
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.
    Campbell K; Naranjo A; Hibbitts E; Gastier-Foster JM; Bagatell R; Irwin MS; Shimada H; Hogarty M; Park JR; DuBois SG
    Eur J Cancer; 2020 Jul; 133():112-119. PubMed ID: 32492633
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Automatic quantification of gene amplification in clinical samples by IQ-FISH.
    Narath R; Lörch T; Rudas M; Ambros PF
    Cytometry B Clin Cytom; 2004 Jan; 57(1):15-22. PubMed ID: 14696059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.